secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001157523-23-000797
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q1 revenue $3.7B flat YoY; non-GAAP EPS $0.40 down from $0.55; reaffirms FY 2023 outlook
--------------------------------------------------------------------------------

- Revenues $3,661M flat YoY (up 4% local currency); GAAP loss per share ($0.18) improved from ($0.86).
- Non-GAAP diluted EPS $0.40 vs $0.55 YoY; adjusted EBITDA $899M, down 21% from $1,135M.
- Non-GAAP gross margin 49.1%, down from 54.2% due to inflationary pressures and unfavorable mix.
- AUSTEDO grew 10% YoY and AJOVY grew 35% (local currency); UZEDY approved for schizophrenia.
- Full-year 2023 outlook reaffirmed: revenue $14.8-15.4B, non-GAAP EPS $2.25-2.55, free cash flow $1.7-2.1B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000115752323000797/0001157523-23-000797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000115752323000797/a53397230.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer